Cutler Group’s Enanta Pharmaceuticals ENTA Stock Holding History

Cutler Group’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-2,500	Closed	-$24K	–	4969
2020 Q3	$24K	Hold	2,500	–	–	﹤0.01%	2314
2020 Q2	$20K	Buy	+2,500	New	+$129K	﹤0.01%	2381
2019 Q2	–	Sell	-2,100	Closed	-$17K	–	4367
2019 Q1	$17K	Buy	+2,100	New	+$188K	﹤0.01%	2142
2018 Q4	–	Sell	-3,000	Closed	-$30K	–	4096
2018 Q3	$30K	Buy	+3,000	New	+$301K	﹤0.01%	1963
2016 Q3	–	Sell	-4,400	Closed	-$34K	–	6822
2016 Q2	$34K	Buy	4,400 +2,400	+120%	+$62.8K	﹤0.01%	2756
2016 Q1	$12K	Sell	2,000 -2,000	-50%	-$55.7K	﹤0.01%	3833
2015 Q4	$32K	Buy	+4,000	New	+$130K	﹤0.01%	2914

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Cutler Group's ENTA Position: Q4 2020 in Review

Cutler Group sold out of Enanta Pharmaceuticals (ENTA) in Q4 2020, closing a stake of 1,820 shares — an estimated $83K sold.

Cutler Group first reported a position in ENTA in Q4 2015 and held it in 13 quarters. The position peaked at $133K in Q1 2019. 151 funds tracked by Wall St. Rank hold ENTA as of Q4 2020.

Cutler Group reported no remaining Enanta Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
Cutler Group sold 1,820 Enanta Pharmaceuticals shares in Q4 2020, an estimated $83K.
Cutler Group first reported a position in Enanta Pharmaceuticals in Q4 2015 and held it in 13 quarters.
Cutler Group's Enanta Pharmaceuticals position peaked at $133K in Q1 2019.
151 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q4 2020.

Based on Cutler Group's 13F filing for Q4 2020, filed 21 Jan 2021.